These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 17075125)

  • 21. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
    Clemons-Miller AR; Chatta GS; Hutchins L; Angtuaco EJ; Ravaggi A; Santin AD; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):917s-924s. PubMed ID: 11300492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
    Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
    J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell distribution and adhesion receptor expression in metastatic melanoma.
    Weishaupt C; Munoz KN; Buzney E; Kupper TS; Fuhlbrigge RC
    Clin Cancer Res; 2007 May; 13(9):2549-56. PubMed ID: 17473183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
    Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
    Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
    Peterson AC; Harlin H; Gajewski TF
    J Clin Oncol; 2003 Jun; 21(12):2342-8. PubMed ID: 12805336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma.
    Dunbar PR; Chen JL; Chao D; Rust N; Teisserenc H; Ogg GS; Romero P; Weynants P; Cerundolo V
    J Immunol; 1999 Jun; 162(12):6959-62. PubMed ID: 10358133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
    Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
    Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
    J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope.
    Mitchell MS; Darrah D; Yeung D; Halpern S; Wallace A; Voland J; Jones V; Kan-Mitchell J
    J Clin Oncol; 2002 Feb; 20(4):1075-86. PubMed ID: 11844833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
    Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T
    Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
    Zippelius A; Batard P; Rubio-Godoy V; Bioley G; Liénard D; Lejeune F; Rimoldi D; Guillaume P; Meidenbauer N; Mackensen A; Rufer N; Lubenow N; Speiser D; Cerottini JC; Romero P; Pittet MJ
    Cancer Res; 2004 Apr; 64(8):2865-73. PubMed ID: 15087405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
    Smith CL; Dunbar PR; Mirza F; Palmowski MJ; Shepherd D; Gilbert SC; Coulie P; Schneider J; Hoffman E; Hawkins R; Harris AL; Cerundolo V
    Int J Cancer; 2005 Jan; 113(2):259-66. PubMed ID: 15386406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
    Lienard D; Avril MF; Le Gal FA; Baumgaertner P; Vermeulen W; Blom A; Geldhof C; Rimoldi D; Pagliusi S; Romero P; Dietrich PY; Corvaia N; Speiser DE
    J Immunother; 2009 Oct; 32(8):875-83. PubMed ID: 19752746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.